ARTICLE | Clinical News

Avastin bevacizumab: Phase IV data

July 26, 2010 7:00 AM UTC

The open-label, international Phase IV SAiL trial in 2,212 patients showed that first-line Avastin plus standard chemotherapy had a low incidence of >=grade 3 adverse events. Rates of thromboembolism, hypertension, bleeding, proteinuria and pulmonary hemorrhage were 8%, 6%, 4%, 3% and 1%, respectively, with 57 deaths as a result of these adverse events. Median TTP and OS were 7.8 and 14.6 months, respectively. Data were published in the Lancet Oncology. ...